Roflumilast

• Chronic Obstructive Pulmonary Disease
• Chronic Bronchitis
• COPD Exacerbation Prevention

Roflumilast (Daliresp) is an oral, once-daily phosphodiesterase-4 (PDE4) inhibitor approved as add-on maintenance therapy to reduce exacerbations in patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of frequent exacerbations. It is not a bronchodilator and does not relieve breathlessness directly; instead it dampens the chronic neutrophilic airway inflammation that drives the exacerbation cycle. For carefully selected patients already on optimized inhaled triple therapy who continue to flare, roflumilast can lower exacerbation frequency by roughly 15-20% in clinical trials. The trade-off is a side-effect profile dominated by GI symptoms, weight loss, and a meaningful neuropsychiatric warning, all of which require active counseling and monitoring rather than a simple prescribe-and-forget approach.

Mechanism of Action

Phosphodiesterase-4 is the dominant phosphodiesterase isoenzyme in inflammatory cells (neutrophils, macrophages, T-lymphocytes, eosinophils) and in airway smooth muscle. PDE4 normally breaks down intracellular cyclic AMP (cAMP), terminating cAMP-dependent anti-inflammatory signaling. By selectively inhibiting PDE4, roflumilast raises intracellular cAMP, which suppresses the release of pro-inflammatory mediators, reduces neutrophil recruitment and activation, decreases mucus production, and dampens the structural remodeling that drives small airway disease. Roflumilast is converted by CYP3A4 and CYP1A2 to roflumilast N-oxide, an active metabolite that contributes the majority of total PDE4 inhibitory activity and has a half-life of about 24 hours, supporting once-daily dosing. The systemic distribution of PDE4 inhibition explains both the GI side effects (nausea, diarrhea, weight loss) and the neuropsychiatric warnings — PDE4 is also expressed in the GI tract and central nervous system. Unlike inhaled corticosteroids, roflumilast does not raise pneumonia risk; unlike chronic azithromycin, it does not promote macrolide resistance. These differential side effect profiles inform when each option is most appropriate.

Clinical Use

Roflumilast occupies a narrow but useful niche in COPD care. The GOLD 2024 strategy document suggests considering roflumilast in patients with chronic bronchitis (defined by chronic productive cough on most days for at least 3 months for 2 consecutive years), an FEV1 less than 50% predicted, and continued exacerbations despite triple therapy with an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta-agonist (such as tiotropium, umeclidinium, vilanterol, salmeterol, formoterol, or fluticasone). It is an alternative to chronic azithromycin for exacerbation reduction in this population. Roflumilast does not replace short-acting bronchodilators like albuterol for acute symptom relief and should not be used in asthma — it is approved only for COPD. Read more about managing COPD in St. Pete's humid climate for practical year-round guidance, and our overview of vaping and e-cigarette health risks for younger patients at risk of COPD-related lung injury. Smoking cessation remains the single most impactful intervention in COPD; pharmacologic aids including varenicline, bupropion, and nicotine replacement should be offered alongside any pharmacotherapy.

How to Take It

Roflumilast is taken as one 500 mcg tablet by mouth once daily, at the same time each day, with or without food. To improve initial tolerability, many clinicians use a 4-week titration starting at 250 mcg daily before increasing to 500 mcg — this dose-escalation strategy has been shown to substantially reduce GI side effects and discontinuation rates in real-world practice. Most GI side effects (nausea, diarrhea, decreased appetite) appear in the first weeks and tend to improve over time; weight loss may be more persistent, with average loss of about 4-5 pounds in clinical trials. Take the tablet with a glass of water and continue your inhaled COPD regimen exactly as prescribed — roflumilast is added to, not in place of, those inhalers. If a dose is missed and it is the same day, take it as soon as you remember; otherwise skip it and continue the next day at the regular time. Do not stop the drug abruptly without discussing first; benefit develops gradually over weeks to months, and discontinuation should be reassessed at the next visit if side effects persist beyond the first month or two. Track weight weekly during the first three months and report unintentional loss of more than 5% of body weight.

Monitoring and Follow-Up

Weight should be checked at every follow-up — clinically meaningful weight loss (more than 5% of body weight or any unintended loss in an underweight patient) is a reason to reconsider therapy. Mood and behavior should be screened at baseline and follow-up: ask specifically about new depression, anxiety, sleep changes, or suicidal thoughts, especially in patients with a personal or family history of mental illness. Periodic CBC and metabolic panel helps track the broader picture, including potential effects of concurrent diuretics or systemic steroids on potassium and glucose. Liver enzymes are monitored if symptoms of hepatic dysfunction develop, and a baseline liver panel is reasonable. Exacerbation rate over 6-12 months is the most important efficacy endpoint; if no reduction is seen by 6 months, discontinuation is reasonable rather than continuing indefinitely. Pulmonary function testing every 1-2 years tracks disease progression. Annual influenza and current COVID-19 vaccination, age-appropriate pneumococcal vaccination (PCV20 or PCV15 followed by PPSV23), and the new RSV vaccine for adults 60 and older are all important in chronic lung disease. Pulmonary rehabilitation remains one of the highest-value interventions in COPD and should always be reinforced.

Special Populations

Roflumilast is contraindicated in moderate to severe hepatic impairment (Child-Pugh B or C); use with caution in mild impairment. No dose adjustment is needed for renal impairment. Older adults can use the standard dose but warrant closer monitoring for psychiatric symptoms, weight loss, and falls. Pregnancy and lactation data are limited; use only if clearly needed and after discussing with the patient. Pediatric use has not been established. Underweight patients (BMI less than 18.5) and patients with cachexia related to advanced lung disease are not good candidates because of the weight-loss risk. Patients with a history of significant depression, suicidal ideation, or psychiatric hospitalization should be considered carefully and only with close mental health follow-up. Patients on strong CYP1A2 or CYP3A4 inhibitors (fluvoxamine, cimetidine, ketoconazole, ciprofloxacin) may have increased exposure; strong inducers (rifampin, phenobarbital, carbamazepine, phenytoin) should be avoided as they substantially reduce roflumilast efficacy.

When to Contact Your Doctor

Seek immediate help for new or worsening depression, anxiety, suicidal thoughts, or unusual behavioral changes — call 988 (the Suicide and Crisis Lifeline) or go to the nearest emergency department for urgent psychiatric crisis. Call the office for unintended weight loss of more than 5% of body weight, severe or persistent diarrhea, persistent nausea or vomiting that interferes with eating, worsening shortness of breath despite treatment that may indicate a brewing exacerbation, dark urine or jaundice, or any new neurologic symptoms. Do not stop the medication abruptly without checking in unless symptoms are severe.

A few practical points distinguish patients who succeed on roflumilast from those who do not. Successful candidates typically have clear chronic bronchitis (frequent productive cough), document at least one moderate or severe exacerbation in the prior year despite optimized inhaled triple therapy, are at a stable or higher BMI, have no significant history of depression or suicidal ideation, and are committed to the slow titration and side-effect monitoring required. Patients who decline because of GI side effects in the first month should not be considered roflumilast failures if they had not yet completed the slower titration; restarting at 250 mcg with food and a planned 4-week up-titration often succeeds. Pulmonary rehabilitation — supervised exercise plus education — produces some of the largest gains in COPD-related quality of life and exercise tolerance and complements all pharmacotherapy. Long-term oxygen therapy is reserved for patients with resting hypoxemia (saturation 88% or below or PaO2 55 mm Hg or below) and changes the trajectory of disease for those who qualify.

For a comprehensive COPD evaluation including pulmonary function testing, vaccine review, smoking cessation support, and personalized exacerbation prevention planning, contact us or schedule a visit at Zimmer Medical Group.